NASDAQ:RPRX Royalty Pharma (RPRX) Stock Forecast, Price & News $26.65 -0.09 (-0.34%) (As of 02:28 PM ET) Add Compare Share Share Today's Range$26.46▼$27.0850-Day Range$26.26▼$31.3852-Week Range$25.92▼$44.47Volume899,659 shsAverage Volume2.09 million shsMarket Capitalization$16.04 billionP/E Ratio61.98Dividend Yield3.00%Price Target$53.25 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Royalty Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside99.0% Upside$53.25 Price TargetShort InterestBearish2.48% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.74Based on 5 Articles This WeekInsider TradingAcquiring Shares$3.84 M Bought Last QuarterProj. Earnings Growth-6.94%From $4.18 to $3.89 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsFinance Sector143rd out of 842 stocksPharmaceutical Preparations Industry14th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.25, Royalty Pharma has a forecasted upside of 99.0% from its current price of $26.76.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.48% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Royalty Pharma has recently increased by 9.47%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 3.01%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 186.05%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 20.57% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 2.6 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Finance companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Royalty Pharma this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows16 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 1,500% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have bought 65.56% more of their company's stock than they have sold. Specifically, they have bought $3,836,300.00 in company stock and sold $2,317,125.00 in company stock.Percentage Held by Insiders18.72% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.03% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to decrease by -6.94% in the coming year, from $4.18 to $3.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 62.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 62.23, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 80.83.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 1.35. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Royalty Pharma (NASDAQ:RPRX) StockRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comRoyalty Pharma Appoints Eric Schneider as Chief Technology OfficerSeptember 21, 2023 | americanbankingnews.comRoyalty Pharma plc (NASDAQ:RPRX) Given Average Rating of "Buy" by AnalystsSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 17, 2023 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Sets New 12-Month Low at $28.22September 12, 2023 | finance.yahoo.comAre Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?September 6, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Buy Rating for Royalty Pharma (RPRX)August 24, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Royalty Pharma (RPRX)August 24, 2023 | markets.businessinsider.comRoyalty Pharma Acquires Royalty On US Net Sales Of Ferring' Adstiladrin For Up To $500 MlnSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 24, 2023 | finance.yahoo.comRoyalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)August 15, 2023 | finance.yahoo.comShareholders in Royalty Pharma (NASDAQ:RPRX) are in the red if they invested three years agoAugust 9, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Royalty Pharma (RPRX)August 8, 2023 | msn.comRoyalty Pharma (RPRX) Surpasses Q2 Earnings and Revenue EstimatesAugust 8, 2023 | msn.comCompared to Estimates, Royalty Pharma (RPRX) Q2 Earnings: A Look at Key MetricsAugust 8, 2023 | seekingalpha.comRoyalty Pharma Q2 2023 Earnings PreviewAugust 8, 2023 | msn.comWhy Royalty Pharma (RPRX) Might Surprise This Earnings SeasonAugust 8, 2023 | finance.yahoo.comRoyalty Pharma Reports Second Quarter 2023 ResultsAugust 8, 2023 | seekingalpha.comRoyalty Pharma plc 2023 Q2 - Results - Earnings Call PresentationAugust 1, 2023 | markets.businessinsider.comRoyalty Pharma (RPRX) Receives a Buy from Goldman SachsJuly 26, 2023 | fool.com2 Dividend Stocks Wall Street Thinks Can Rise by 50%July 18, 2023 | finance.yahoo.comRoyalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023July 17, 2023 | finance.yahoo.comRoyalty Pharma Declares Third Quarter 2023 DividendJuly 12, 2023 | msn.comMorgan Stanley Reiterates Royalty Pharma plc - (RPRX) Overweight RecommendationJune 18, 2023 | finance.yahoo.comInstitutional owners may consider drastic measures as Royalty Pharma plc's (NASDAQ:RPRX) recent US$453m drop adds to long-term lossesJune 15, 2023 | msn.comImplied Volatility Surging for Royalty Pharma (RPRX) Stock OptionsJune 14, 2023 | barrons.comS&P 500 Futures Climb in Premarket Trading; Royalty Pharma, Coherent LeadJune 10, 2023 | msn.comRoyalty Pharma: A Strong Start To 2023 Bodes Well For The FutureSee More Headlines Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Company Calendar Last Earnings8/08/2023Ex-Dividend for 9/15 Dividend8/17/2023Dividend Payable9/15/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorFinance Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees51Year Founded1996Price Target and Rating Average Stock Price Forecast$53.25 High Stock Price Forecast$60.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+100.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.43 Trailing P/E Ratio61.84 Forward P/E Ratio6.36 P/E Growth1.35Net Income$42.83 million Net Margins10.84% Pretax Margin19.94% Return on Equity29.03% Return on Assets16.73% Debt Debt-to-Equity Ratio0.62 Current Ratio2.52 Quick Ratio2.52 Sales & Book Value Annual Sales$2.24 billion Price / Sales7.15 Cash Flow$3.72 per share Price / Cash Flow7.14 Book Value$15.69 per share Price / Book1.69Miscellaneous Outstanding Shares601,820,000Free Float489,162,000Market Cap$16.00 billion OptionableNot Optionable Beta0.39 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman & CEO Mr. Terrance P. CoyneExec. VP & CFOMr. George Wingate Lloyd (Age 64)Exec. VP of Investments & Chief Legal Officer Comp: $4.35MMr. Christopher Hite (Age 56)Vice Chairman & Exec. VP Comp: $4.35MDr. Marshall Urist M.D.Ph.D., Exec. VP and Head of Research & InvestmentsMr. Arthur R. McGivern J.D.Exec. VP of Investments & Gen. CounselMr. Ashwin Pai M.D.Exec. VP of InvestmentsMs. Kristin Stafford (Age 41)Sr. VP & Chief Accounting Officer Dr. James Folmar Reddoch Ph.D. (Age 53)Exec. VP of Investments & Chief Scientific Officer Mr. George Grofik C.F.A.CPA, Sr. VP and Head of Investor Relations & CommunicationsMore ExecutivesKey CompetitorsRegions FinancialNYSE:RFKB Financial GroupNYSE:KBCincinnati FinancialNASDAQ:CINFW. R. BerkleyNYSE:WRBCoinbase GlobalNASDAQ:COINView All CompetitorsInsiders & InstitutionsBarclays PLCBought 670,204 shares on 9/21/2023Ownership: 0.183%California State Teachers Retirement SystemBought 13,861 shares on 8/21/2023Ownership: 0.101%Nuveen Asset Management LLCBought 35,919 shares on 8/16/2023Ownership: 0.172%Neo Ivy Capital ManagementBought 38,961 shares on 8/16/2023Ownership: 0.006%Walleye Capital LLCBought 2,167 shares on 8/15/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions RPRX Stock - Frequently Asked Questions Should I buy or sell Royalty Pharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks. What is Royalty Pharma's stock price forecast for 2023? 4 brokerages have issued twelve-month target prices for Royalty Pharma's shares. Their RPRX share price forecasts range from $48.00 to $60.00. On average, they predict the company's stock price to reach $53.25 in the next year. This suggests a possible upside of 100.3% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts. How have RPRX shares performed in 2023? Royalty Pharma's stock was trading at $39.52 at the start of the year. Since then, RPRX shares have decreased by 32.7% and is now trading at $26.59. View the best growth stocks for 2023 here. When is Royalty Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our RPRX earnings forecast. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) posted its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.02. The biopharmaceutical company had revenue of $545 million for the quarter, compared to the consensus estimate of $538.52 million. Royalty Pharma had a trailing twelve-month return on equity of 29.03% and a net margin of 10.84%. How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma? Royalty Pharma announced a quarterly dividend on Monday, July 17th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.20 per share on Friday, September 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date is Thursday, August 17th. Read our dividend analysis for RPRX. What ETFs hold Royalty Pharma's stock? ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE), Formidable ETF (FORH), Fidelity Disruptive Medicine ETF (FMED), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), VictoryShares Free Cash Flow ETF (VFLO), VictoryShares Nasdaq Next 50 ETF (QQQN) and Invesco Nasdaq Biotechnology ETF (IBBQ). Is Royalty Pharma a good dividend stock? Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.80 per share and currently has a dividend yield of 3.01%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 186.05%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, RPRX will have a dividend payout ratio of 20.57% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO). When did Royalty Pharma IPO? (RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. What is Royalty Pharma's stock symbol? Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX." Who are Royalty Pharma's major shareholders? Royalty Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.42%), Baillie Gifford & Co. (3.05%), JPMorgan Chase & Co. (1.44%), State Street Corp (1.35%), Geode Capital Management LLC (1.01%) and abrdn plc (0.64%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Adage Capital Partners Gp, LL, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Royalty Pharma's stock price today? One share of RPRX stock can currently be purchased for approximately $26.59. How much money does Royalty Pharma make? Royalty Pharma (NASDAQ:RPRX) has a market capitalization of $16.00 billion and generates $2.24 billion in revenue each year. The biopharmaceutical company earns $42.83 million in net income (profit) each year or $0.43 on an earnings per share basis. How can I contact Royalty Pharma? Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The official website for the company is www.royaltypharma.com. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at ir@royaltypharma.com. This page (NASDAQ:RPRX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.